Vesna VC backs P3 Therapeutics
Southeast European deep-tech fund Vesna VC has invested in P3 Therapeutics, backing our multi-target approach to chronic inflammation. Financial terms were not disclosed.
Vesna VC, the Southeast European deep-tech venture fund with offices in Zagreb and Ljubljana, has invested in P3 Therapeutics. The deal was announced by our founder and executive chairman Miroslav Harjaček, who thanked Vesna VC partners Srdja Iveković, Dalibor Marijanović and Nina Dremelj for their backing. No financial details were disclosed.
Why it matters
P3T develops small chemical molecules that activate three anti-inflammatory targets at once — Triple Target Activation — starting with spondyloarthritis, where a second-line therapy is practically non-existent. Multi-target approaches are gaining traction across drug development, and inflammation remains one of the largest addressable markets in pharma, underpinning conditions from cardiovascular disease to autoimmune disorders.
The investment positions P3T to build early clinical credibility: it funds further synthesis of our TTA molecules, the ex vivo testing programme with the Faculty of Chemical Engineering and Technology in Zagreb (FKIT), our R&D partner, and the preclinical work that follows. It also adds a named regional investor alongside the European instruments — InvestEU, the European Investment Fund and national development banks — that already support the company.
About Vesna VC
Vesna VC manages a deep-tech venture fund focused on Central and Eastern Europe, with a particular focus on Croatia and Slovenia. P3 Therapeutics is listed in its portfolio with FKIT Zagreb as R&D partner.
Source: Vesna VC backs Croatian biotech P3 Therapeutics — Dealroom.co, June 2026.